Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.51 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | TFPI | P10646 | 1/20 | 0.49 |
| ▸ | VIPR2 | P41587 | 4/20 | 0.49 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.49 |
| ▸ | GLP1R | P43220 | 4/20 | 0.48 |
| ▸ | SCTR | P47872 | 1/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3193504 | 0.91 | GLP1R (0.48) | BACE1CTSDTFPIVIPR1GLP1R | |
| SCHEMBL30297185 | 0.89 | TFPI (0.58) | TFPIVIPR1GLP1RSCTR | |
| SCHEMBL2159226 | 0.86 | NPY4R (0.50) | — | |
| SCHEMBL29871066 | 0.85 | VIPR2 (0.56) | BACE1CTSDTFPIVIPR2VIPR1 | |
| SCHEMBL29592929 | 0.85 | TFPI (0.63) | TFPIVIPR2VIPR1GLP1RSCTR | |
| SCHEMBL29972780 | 0.85 | TFPI (0.63) | TFPIVIPR2VIPR1GLP1RSCTR | |
| SCHEMBL8973636 | 0.84 | TFPI (0.62) | TFPIVIPR2VIPR1GLP1RSCTR | |
| SCHEMBL29973057 | 0.84 | GLP1R (0.61) | TFPIVIPR2GLP1RSCTR | |
| SCHEMBL8973422 | 0.84 | TFPI (0.61) | TFPIVIPR2VIPR1GLP1RSCTR | |
| SCHEMBL8973446 | 0.84 | TFPI (0.61) | TFPIVIPR2VIPR1GLP1RSCTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017633-B2 | Administering [3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide; hypertension, hyperlipidemia, hyperuricemia, gout and hypercoagulability | NYCOMED GMBH (DE) | 2011-09-13 | — | — | US | disclosed |
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | KONINKLIJKE HILIPS ELECTRONICS, N.V. (NL) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | NOS3, PLAT, PTGIS | BACE1 2701/4885CTSD 615/4885TFPI 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.